Evaluating immunological outcomes associated with histotripsy treatment in canine osteosarcoma: a comparative human oncology model

Abstract Osteosarcoma (OS), the most commonly occurring primary bone tumor in dogs and humans, has deficient treatment options dismal survival outcomes. Spontaneously OS shares numerous similarities with humans greater prevalence, allowing dog to serve as an informative comparative oncology model. The objective of this study was investigate non-thermal focused ultrasound technique histotripsy innovative option for OS. Histotripsy potential both ablate stimulate antitumor immune response mitigate metastatic disease, leading cause death To immunological outcomes associated OS, we delivered client-owned canine patients (n=29) utilized in-vitro model cross species comparisons between human, dog, mouse. ablation led a significantly expression activation markers CD80 CD62L on circulating monocytes, at 1- 5-days post (DPH), respectively. We observed production TGFβ monocytes 3 DPH compared baseline. On independent patient basis, population CD5 +CD4 +and +CD8 +cells within treated region untreated changes genetic signature also indicated activation. Across macrophage (CD80, CD62L, CD86), upregulation genes cell chemotaxis pro-inflammatory response. Our results indicate that leads strong target disease. NIH (1R21 EB030182-01), Focused Ultrasound Foundation (PLL7GBVK FUSF-RAP-823R1), American Kennel Club (Canine Health No. 02773)